UBS Group
ABCL icon

UBS Group’s AbCellera Biologics ABCL Stock Holding History

UBS Group’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-30,000
Closed -$304K – 9526
2022
Q4 		$304K Sell
30,000
-219,100
-88% -$2.53M ﹤0.01% 5112
2022
Q3 		$2.46M Buy
+249,100
New +$2.73M ﹤0.01% 2974

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group's ABCL Position: Q1 2026 in Review

UBS Group increased its AbCellera Biologics (ABCL) stake by 117% in Q1 2026, buying an estimated $8.17M and bringing the position to 4,209,052 shares worth $14.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2923.

UBS Group first reported a position in ABCL in Q4 2020 and has held it in 21 quarters since. 138 funds tracked by Wall St. Rank hold ABCL as of Q1 2026.

  • UBS Group held 4,209,052 shares of AbCellera Biologics worth $14.7M as of Q1 2026.
  • UBS Group bought 2,269,643 AbCellera Biologics shares in Q1 2026, an estimated $8.17M.
  • AbCellera Biologics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #2923 holding.
  • UBS Group first reported a position in AbCellera Biologics in Q4 2020 and has held it in 21 quarters since.
  • 138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.